Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.

ABSTRACT:

Aim

To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection.

Methods

A total of 143 patients (83.1% of the 172 participants in the phase II study) participated in the follow-up study. Of these patients, 50 had received no treatment, 48 had received 160 mg/d PI-88, and 45 had received 250 mg/d PI-88 during the phase II trial. Safety parameters and the following efficacy endpoints were investigated: (1) time to recurrence; (2) disease-free survival; and (3) overall survival.

Results

PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after tre

SUBMITTER: Liu CJ 

PROVIDER: S-EPMC4145780 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature